[Efficacy and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure in routine practice]. / Ustekinumab dans le rhumatisme psoriasique après échec des anti-TNFα en pratique courante.
Therapie
; 71(3): 281-6, 2016 Jun.
Article
en Fr
| MEDLINE
| ID: mdl-27235651
ABSTRACT
PURPOSE:
Evaluation of effectiveness and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure.METHODS:
We conducted a retrospective and monocentric study. The evaluation of articular and cutaneous effectiveness by the patient was made with numeric scale and satisfaction scale and by the physician during a rhumatological-dermatological consultation. The safety was analyzed by collecting the adverse effects.RESULTS:
Nine patients with anti-TNF failure were included. Five of them stopped the treatment because of severe adverse effects. The mean duration treatment of ustekinumab was 24 months. Articular and cutaneous effectiveness were respectively 4.4/10 and 6.7/10. Two thirds of the patients were "satisfied" and one third could stop any analgesic treatment. The mean PASI score decreased from 8.4 to 1.7 after 3 months treatment. Only minor adverse effects were collected and there were no recidivism of the adverse effects observed with anti-TNFα.CONCLUSION:
Ustekinumab is an effective and safe alternative for patients with anti-TNFα failure in psoriatic arthritis.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Artritis Psoriásica
/
Factor de Necrosis Tumoral alfa
/
Satisfacción del Paciente
/
Fármacos Dermatológicos
/
Ustekinumab
Tipo de estudio:
Observational_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Fr
Revista:
Therapie
Año:
2016
Tipo del documento:
Article